Latest news and press releases about Autolus Therapeutics plc (AUTL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL).
Price
| Price | $1.87 |
| Market Cap | $498M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 6.51 |
| EV / EBITDA | -2.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -178.58% |
| Return on Invested Capital | -57.49% |
| Return on Assets | -56.77% |
| Gross Margin | 15.66% |
| Operating Margin | -210.76% |
| Net Margin | -238.62% |
Related companies: ADCT · ANNX · AURA · BNTC · LBRX · NMRA · QSI
Explore sector: Healthcare · Biotechnology
More sections of AUTL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks